KEGG   DRUG: PalivizumabHelp
Entry
D02737                      Drug                                   

Name
Palivizumab (INN);
Palivizumab (genetical recombination) (JAN);
Synagis (TN)
Product
Remark
Therapeutic category: 6250
ATC code: J06BB16
Product: D02737<JP/US>
Efficacy
Antiviral, Anti-RS virus humanized antibody
  Disease
Respiratory syncytial virus infection [DS:H00401]
Comment
Monoclonal antibody
Target
RSV F protein
Structure map
map07044  Antiviral agents
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J06 IMMUNE SERA AND IMMUNOGLOBULINS
   J06B IMMUNOGLOBULINS
    J06BB Specific immunoglobulins
     J06BB16 Palivizumab
      D02737  Palivizumab (INN)
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D02737  Palivizumab (INN); Palivizumab (genetical recombination) (JAN)
Antiinfectives [br08350.html]
 Antivirals
  D02737
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D02737
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D02737
BRITE hierarchy
Other DBs
CAS: 188039-54-5
PubChem: 47205815
DrugBank: DB00110

» Japanese version   » Back

DBGET integrated database retrieval system